Bevacizumab-Induced Hypertension Indicative of Better Survival in Glioblastoma
the Cancer Therapy Advisor take:
When compared to normotensive patients with recurrent glioblastoma (GBM), individuals who developed bevacizumab-induced hypertension experienced increased progression-free survival (PFS) and overall survival (OS), according to an article published online in Cancer.
In this study, 82 patients with recurrent GBM were identified as being treated using bevacizumab within the Emory Healthcare system from 2007 through 2012. Of the 82 patients, 30 developed bevacizumab-induced hypertension. The patients were categorized as normotensive or hypertensive based on if their hypertension was drug-induced.
Results showed that the median follow-up period was 19.7 months and the median time to the development of drug-induced hypertension was 21 days.
Furthermore, the median PFS was 2.5 months (95% CI: 1.6, 3.0) for the normotensive group and 6.7 months (95% CI: 4.6, 10.0) for the hypertensive group (PP<0.001).
The study suggests that drug-induced hypertension resulting from treatment with bevacizumab may be a physiologic marker of outcome in individuals with recurrent GBM.
The patients with bevacizumab-induced hypertension displayed greater PFS and OS compared with normotensive patients.
Glioblastoma patients who developed bevacizumab-induced hypertension experienced increased survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer